Clinical Trial Update: CART-19 Post-ASCT for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating CART-19 post-autologous stem cell transplant for multiple myeloma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CART-19 (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: University of Pennsylvania | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2020-03-04